Arcturus (ARCT) Q4 2025 earnings review
Revenues Collapse as Milestones Dry Up, But Cost Controls Secure the Future
Arcturus is transitioning through a predictable 'revenue valley.' Q4 revenue reversed sharply, falling 68% YoY to just $7.2 million, as development milestones from the CSL collaboration were exhausted following the commercial transition of the KOSTAIVE vaccine. Consequently, the Q4 net loss widened sequentially to $29.1 million. However, investors should look past the top-line shock. The aggressive cost-cutting pivot announced earlier in 2025 is working: full-year R&D expenses decelerated by 42%. By practically halving its R&D burn, Arcturus has successfully extended its cash runway to Q2 2028, ensuring it can read out critical Phase 2 data for its rare disease pipeline without the threat of near-term dilution.
🐂 Bull Case
Management successfully executed its strategic pivot. Despite the Q4 sequential revenue drop, strong FY cost reductions have extended the cash runway into Q2 2028, eliminating financing overhangs.
The ARCT-032 (CF) program cleared its 28-day 15mg safety hurdle with no tolerability issues, allowing the crucial 12-week Phase 2 efficacy study to begin in H1 2026.
🐻 Bear Case
With CSL development milestones largely complete, Arcturus relies on commercial profit-sharing. However, CSL must first recoup its development costs, meaning meaningful vaccine revenue is likely years away.
The indefinite delay of the KOSTAIVE BLA in the US severely limits the near-term commercial ceiling for the company's only approved product.
⚖️ Verdict: ⚪
Neutral. The optical collapse in revenue is ugly but was entirely expected. The company's value now rests solely on the clinical success of its CF and OTC programs, and management has secured the necessary capital to reach those milestones.
Key Themes
The CSL Revenue Valley Contradicts Commercial Narrative
Management heavily touts the global commercialization of KOSTAIVE (including the Jan 2026 UK MHRA approval), but the financials tell a contradictory story. Q4 revenue reversed to a multi-year low of $7.2M (down from $22.8M YoY). Why? The lucrative development milestones from CSL are ending, and Arcturus won't see direct profit-sharing until CSL recoups its development costs. The commercial success of the vaccine is currently divorced from Arcturus's near-term cash generation.
Extreme Financial Discipline Extends Runway
The strategic decision to pause early-stage R&D and focus exclusively on late-stage rare diseases has yielded massive savings. FY25 R&D expenses decelerated sharply to $112.2M, down 42% from $195.2M in FY24. This aggressive cost management is the sole reason the company can now guide to a cash runway extending into Q2 2028.
ARCT-032 Clears Critical Safety Hurdle
A major risk for inhaled mRNA therapeutics is lung tolerability over chronic dosing. Arcturus completed 28-day dosing at the highest 15mg cohort for ARCT-032 (Cystic Fibrosis) with no reported safety issues. The program is now permitted to accelerate into a larger (up to 20 patients) 12-week Phase 2 study in H1 2026, which will be the ultimate test of FEV1 (lung function) efficacy.
Macro & Regulatory Headwinds Stalling Pipeline
The broader regulatory environment for mRNA post-pandemic remains a massive headwind. The FDA's 'sudden changes in regulatory requirements' effectively forced Arcturus to abandon its US KOSTAIVE ambitions indefinitely. This regulatory uncertainty creates a shadow over how the FDA will treat the novel endpoints (like HRCT imaging or 15N-ureagenesis) the company hopes to use for its rare disease therapies.
LUNAR & sa-mRNA Innovation Advancing
Despite US regulatory hurdles, the underlying technology continues to win validation. The UK's MHRA approval of KOSTAIVE in Jan 2026 marks another nod for the self-amplifying mRNA (sa-mRNA) platform. Meanwhile, the H5N1 (avian flu) BARDA program continues to show durable immune responses up to 8 months post-vaccination at very low doses (1.5 to 12 mcg), proving the platform's dose-sparing advantages.
ARCT-810 Pivot to Dual-Population Strategy
The ARCT-810 (OTC Deficiency) strategy is expanding. Management is now targeting both adults with late-onset disease (targeting glutamine biomarkers) and young children with severe forms (targeting ammonia). Success hinges entirely on the upcoming H1 2026 Type C regulatory meetings to secure FDA alignment on this pivotal trial design.
IP Litigation Cloud
The company disclosed an ongoing lawsuit filed in September 2025 against AbbVie and Capstan Therapeutics. While details are sparse in the current release, IP battles over LNP delivery and mRNA constructs can be a costly distraction and a drain on G&A resources, which spiked in Q4.
Other KPIs
Stable. Down from $293.9M at the end of FY24. The full-year cash burn of ~$61M validates management's guidance that they are sufficiently capitalized into Q2 2028.
Accelerating. Up from $10.4M in Q3 and $12.4M a year ago. Management attributed this sudden bump to the acceleration of employee stock options, rather than a structural increase in administrative bloat.
Guidance
Accelerating/Expanding from the prior 'into 2028' guidance. This explicitly covers the company through the initiation and readout of the upcoming 12-week Phase 2 CF trial.
Decelerating. Management expects G&A to trend down primarily due to lower share-based compensation costs following the Q4 option acceleration.
The 12-week Phase 2 study for up to 20 Class I CF participants is on track to begin in H1 2026, officially transitioning the program from safety validation to efficacy testing.
Type C regulatory meetings to determine the pivotal Phase 3 pathway for both adult and pediatric populations are scheduled for the first half of 2026.
Key Questions
Details on the AbbVie/Capstan Lawsuit
You disclosed an ongoing lawsuit against AbbVie and Capstan Therapeutics filed in September 2025. Could you outline the specific IP or trade secrets at the center of this dispute, and how it might impact your G&A run rate?
CSL Cost Recoupment Timeline
With Q4 revenues dropping significantly due to the transition of the CSL collaboration, what is the estimated timeline or sales volume required for CSL to recoup its 40% development costs before Arcturus begins seeing direct profit-sharing?
CF Phase 2 Efficacy Bar
For the upcoming 12-week Phase 2 study of ARCT-032, you will be monitoring FEV1 and LCI. What specific numerical improvement in FEV1 do you believe the FDA will require to grant a pivotal Phase 3 design, given the precedent set by modulators?
US BLA Revival?
Given the UK MHRA approval of KOSTAIVE in January 2026, are there any ongoing back-channel discussions with the FDA, or is the US market permanently closed for this specific asset?